Affiliations 

  • 1 Department of Pharmaceutical Chemistry, Raghavendra Institute of Pharmaceutical Education and Research (Autonomous), Anantapuramu, Andhra Pradesh, India. [email protected]
  • 2 Department of Pharmacology, Siddha Central Research Institute, Central Council for Research in Siddha, Ministry of AYUSH, Chennai, Tamil Nadu, India
  • 3 College of Pharmacy, Riyadh ELM University, Riyadh, Kingdom of Saudi Arabia, Riyadh
  • 4 Department of Life Science and Bioinformatics, Assam University, Silchar, India
  • 5 Faculty of Pharmaceutical Sciences, UCSI University, Cheras, Kuala Lumpur, Malaysia
  • 6 Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Hajipur, Bihar, India
  • 7 Faculty of Pharmacy, Dr. M.G.R. Educational and Research Institute, Chennai, India
Adv Exp Med Biol, 2022;1391:161-179.
PMID: 36472822 DOI: 10.1007/978-3-031-12966-7_10

Abstract

Prostate cancer is the most commonly diagnosed and frequently occurred cancer in the males globally. The current treatment strategies available to treat prostate cancer are not much effective and express various adverse effects. Hence, there is an urgent need to identify novel treatment that can improve patient outcome. From times immemorial, natural products are highly recognized for novel drug development for various diseases including cancer. Cancer cells generally maintain higher basal levels of reactive oxygen species (ROS) when compared to normal cells due to its high metabolic rate. However, initiation of excess intracellular ROS production can not be tolerated by the cancer cells and induce several cell death signals which are in contrast to normal cells. Therefore, small molecules of natural origin that induce ROS can potentially kill cancer cells in specific and provide a better opportunity to develop a novel drug therapy. In this review, we elaborated various classes of medicinal compounds and their mechanism of killing prostate cancer cells through direct or indirect ROS generation. This can generate a novel thought to develop promising drug candidate to treat prostate cancer patients.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.